WO2013078659A1 - Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins - Google Patents

Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins Download PDF

Info

Publication number
WO2013078659A1
WO2013078659A1 PCT/CN2011/083302 CN2011083302W WO2013078659A1 WO 2013078659 A1 WO2013078659 A1 WO 2013078659A1 CN 2011083302 W CN2011083302 W CN 2011083302W WO 2013078659 A1 WO2013078659 A1 WO 2013078659A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
accordance
milk
wolfberry
blood vessel
Prior art date
Application number
PCT/CN2011/083302
Other languages
English (en)
Inventor
Peifang Zhang
Peter Bucheli
Olivier Ballevre
Weiguo Zhang
Youyou ZHAO
Original Assignee
Nestec S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec S.A. filed Critical Nestec S.A.
Priority to CN201180075659.8A priority Critical patent/CN104010649A/zh
Priority to PCT/CN2011/083302 priority patent/WO2013078659A1/fr
Publication of WO2013078659A1 publication Critical patent/WO2013078659A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients

Definitions

  • the invention relates generally to methods and compositions for preventing, reducing, or treating damage caused by impaired blood vessel elasticity and particularly to methods and compositions that comprise wolfberry for preventing, reducing, or treating damage caused by impaired blood vessel elasticity .
  • Wolfberry is a fruit from the family Solanaceae in the species Lycium barbarum or Lycium chinense .
  • Wolfberry is known by several names, e.g. goji berry.
  • Wolfberry is known as an agent in Chinese medicine and is claimed to be useful for many purposes, e.g., enhancing the immune system, improving vision, protecting the liver, improving circulation, and boosting sperm production.
  • enhancing the immune system e.g., improving vision, protecting the liver, improving circulation, and boosting sperm production.
  • US Patent Application 20060088643 discloses that wolfberry compositions or wolfberry extracts can be used to strengthen muscles and bone, protect liver function, replenish the vital essence, treat diabetes, prevent aging, and improve visual acuity .
  • US200710212433 discloses a method of improving absorption of an antioxidant by co-administering at least one antioxidant with an effective amount of a Gac Fruit extract, e.g., wolfberry .
  • WO05018656A1 discloses using wolfberry extract to prevent brain nerve cell death and Alzheimer's disease.
  • US20050238654 discloses that wolfberry can be used to lower blood pressure and cholesterol levels, acting mainly on the liver and kidney.
  • US20050281902 discloses a method for inhibiting metastasis of colon, lung, liver, kidney, breast, or cervical cancer using Lycium barbarum extract.
  • Lycium barbarum helps improve vision and prevent headaches and dizziness caused by liver and kidney deficiencies and may be effective in treating mild diabetes.
  • WO2010014245 teaches that lacto-wolfberry extract is very effective in protecting brains against ischemia (stroke) - induced damage .
  • Strokes include three major types; ischemic strokes, hemorrhagic strokes, and transient ischemic attacks.
  • Ischemic strokes occur when a blood vessel supplying blood to the brain is blocked.
  • Hemorrhagic strokes occur when a blood vessel supplying blood to the brain ruptures.
  • Hemorrhagic strokes can be classified as intracerebral or subarachnoid depending on whether the blood goes into or around the brain.
  • Transient ischemic attacks are minor or warning strokes, typically lasting less than one hour.
  • Strokes are a leading cause of functional impairment in our society today, causing institutionalization or life with a permanent disability. In the US, about 610,000 new strokes occur each year and in China, about 2,000,000 new strokes occur annually. Primary prevention of stroke is hence a key goal in research today.
  • the present inventors have focused on improving blood vessel elasticity, e.g. in order to prevent or delay the onset of hemorrhagic stroke and/or to prevent or delay cerebral aneurysms .
  • Unruptured cerebral aneurysms are a common incidental finding at autopsy and during cerebral aniography and approximately 1- 6% of human beings harbor an unruptured cerebral aneurysm (Ronkainen et al . , Stroke. 1998 Feb; 29 (2) : 359-62) .
  • An aneurysm is a ballooning or bulging out of a weakened area of the wall of an artery or vein.
  • SAH subarachnoid hemorrhage
  • SAH is the most expensive stroke subtype given the frequent need for surgery and intensive care monitoring with high levels of subsequent morbidity (Johnston et al . , Neurology. 1998 May; 50 (5) : 1413-8) .
  • Surgical clipping or intravascular intervention prevents SAH recurrence but leads to additional morbidity and mortality (Raaymakers at al . , Stroke. 1998 Aug; 29(8) : 1531-8) .
  • cerebral aneurysms rupture and reduction aneurysms development is of paramount importance.
  • Hypertension, hemodynamic stress, age (>50 years) , atherosclerosis, smoking, alcohol consumption, gender differences and genetic abnormalities are involved in the pathogenesis of cerebral aneurysm .
  • the present inventors were able to show that the administration of wolfberry preparations to rats delayed the onset of hemorrhagic brain damage in SHRsp animals.
  • Wolfberry treatment allowed to improve blood vessel elasticity and had an effect on preventing a loss of blood vessel elasticity .
  • TNF- is currently believed to be a key player in inflammation and degradation damage of the artery.
  • TNF-a might mediate inflammation in cerebral aneurysms which could be important for aneurysm development and growth.
  • wolfberry has a direct effect on preventing, reducing or treating the cerebral aneurysms process and its rupture, and the damage caused by cerebral aneurysms process and rupture.
  • the present invention relates in part to a composition comprising wolfberries or an extract thereof for use in the treatment, amelioration or prevention of disorders linked to impaired blood vessel elasticity.
  • the present invention also relates to the use of wolfberries or an extract thereof for the preparation of a composition for the treatment, amelioration or prevention of disorders linked to impaired blood vessel elasticity.
  • wolfberries or an extract thereof means one or more fruits from the family Solanaceae in the species Lycium barbarum or Lycium chinense and extracts or portions thereof.
  • Wolfberries may be used in any form, e.g. in the form of fresh, ripe fruits, as dried fruits, as frozen fruits, or as parts thereof.
  • Fruits may also be used in the form of fresh, concentrated or dried materials, for example, air or freeze dried material. It is however preferred to use dried ripe fruit .
  • the composition of the present invention may be for use in the maintenance of heart health and/or in the prevention or treatments of heart diseases, for example. These heart diseases may be linked to coronary artery aneurysms. The incidence of coronary artery aneurysms ranges from 0.3% to 5.3% of the population.
  • the composition of the present invention may also be for use in the prevention of brain damage, for example. Reduced blood vessel elasticity may result in blood vessel ruptures in and around the brain which may lead to severe - and often irreversible - brain damage.
  • the brain damage may for example be a hemorrhagic brain damage. Hemorrhagic brain damage may be a hemorrhagic stroke which occurs when a blood vessel bursts inside the brain.
  • the brain is very sensitive to bleeding which may irritate the brain tissue and/or cause swelling which in turn increases pressure on the brain and presses it against the skull.
  • Hemorrhagic brain damage may for example be an intracerebral hemorrhage where the bleeding occurs in the brain or a subarachnoid hemorrhage where the bleeding occurs in the area between the brain and the tissues that cover the brain.
  • the composition of the present invention may also be for use in preventing or delaying the onset of a hemorrhagic stroke.
  • composition of the present invention may also be for use in the treatment of prevention of aneurisms, for example cerebral aneurysms.
  • a cerebral or brain aneurysm is a cerebrovascular disorder in which weakness in the wall of a cerebral artery or vein causes a localized dilation or ballooning of the blood vessel.
  • Such aneurisms are dangerous as small, unchanging aneurysms typically produce almost no symptoms and remain, hence, often unnoticed .
  • composition of the present invention may advantageously be used for preventing or delaying the rupture of aneurysms.
  • Blood vessel elasticity is in particular important for arteries which expand during heart contraction because of systolic pressure, and contract when the heart expands and refills because of diastolic pressure.
  • the blood vessel an arterial blood vessel.
  • composition of the present invention allows it to deliver the above mentioned health benefits without influencing blood pressure.
  • the inventors believe that this is quite unique as most compositions that are currently used for the purposes described above reduce blood pressure.
  • composition of the present invention may be to be administered to subjects at risk of developing aneurysms and/or stroke, but with a normal or low blood pressure.
  • a normal blood pressure may be a systolic blood pressure of about 90-119 mmHg and a diastolic blood pressure of about 60-79 mmHg.
  • a low blood pressure may be a systolic blood pressure of about ⁇ 90 mmHg and a diastolic blood pressure of about ⁇ 60 mmHg.
  • composition of the present invention may be to be administered to subjects on a regular basis.
  • regular basis means at least monthly dosing with wolfberry and more preferably weekly dosing. More frequent dosing or consumption, such as twice or three times weekly, is preferred in certain embodiments. Still more preferred are regimens that comprise at least once daily consumption, e.g., when wolfberry is a component of a food composition that is consumed at least once daily.
  • composition of the present invention may be a part of one or more daily meals.
  • composition of the present invention may be to be administered to subjects as part of their regular diets, for example as part of their breakfast.
  • compositions are administered in an amount sufficient to at least partially cure or arrest the symptoms of the disease and its complications.
  • An amount adequate to accomplish this is defined as "a therapeutically effective dose”. Amounts effective for this purpose will depend on a number of factors known to those of skill in the art such as the severity of the disease and the weight and general state of the patient.
  • compositions according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease in an amount that is sufficient to at least partially reduce the risk of developing a disease.
  • a prophylactic effective dose Such an amount is defined to be "a prophylactic effective dose”.
  • the precise amounts depend on a number of patient specific factors such as the patient's state of health and weight.
  • compositions of the present invention may be to be administered in a therapeutically effective dose or a prophylactic effective dose.
  • composition of the present invention may be to be administered in an amount corresponding to about 0.1 to about 3000 mg wolfberry/kg body weight/day, preferably from about 10 to about 2000 mg wolfberry /kg body weight /day, most preferably from about 50 to about 1000 mg wolfberry /kg body weight/day .
  • the composition of the present invention may be to be administered to adults and in particular to elderly subjects.
  • a subject may be considered as "elderly" if it has surpassed the first half of its average expected lifespan in its country of origin, preferably, if it has surpassed the first two thirds of the average expected lifespan in its country of origin, more preferably if it has surpassed the first three quarters of the average expected lifespan in its country of origin, most preferred if it has surpassed the first four fifths of the average expected lifespan in its country of origin.
  • the subject is a human, it may be > 50 years old, over 60 years old, over 70 years old, or over 80 years old, for example.
  • composition of the present invention may be to be administered to humans or pets, for example companion animals such as cats or dogs.
  • Wolfberries may be used as such or as parts or an extract thereof .
  • Watery, alcoholic or oily extracts may be used.
  • a skilled artesian can well prepare such extracts and furthermore, suitable wolfberry extracts can be obtained commercially.
  • the wolfberry extract is a lacto-wolfberry extract.
  • wolfberries may be provided as a primary composition comprising wolfberries or a part thereof and milk or a milk- protein containing carrier.
  • lacto-wolfberry extract is described in detail in WO2005/092121, which is hereby fully incorporated into this text by reference.
  • such a primary composition may be obtainable by a process comprising the steps of: i) mixing and milling wolfberry material in milk or milk protein-containing liquid medium, ii) optionally separating insoluble fibers to obtain an aqueous suspension iii) optionally pasteurizing the resulting suspension iv) optionally adding synthetic or natural bioactive components during the processing, and v) further optionally drying the suspension to obtain a powder .
  • the milk or milk protein can be derived from animal or plant origin, or from mixtures thereof.
  • the milk is cow milk, lama milk, buffalo milk, goat milk, sheep milk, vegetable milk, in particular soy milk or a mixture thereof.
  • Milk protein is to be understood as a protein fraction obtainable from one or more of the milk types listed above.
  • Milk protein may for example be whey proteins, -lactalbumin, ⁇ -lactoglobulin, bovine serum albumin, acid casein, caseinates, a-casein, ⁇ -casein, ⁇ -casein, or mixtures thereof.
  • the primary composition is a miscible composition.
  • the primary composition comprises milk or a milk-protein containing carrier and has a close profile of the essential active components of whole wolfberries, it has a good stability, miscibility and/or dispersibility in aqueous systems .
  • the primary composition has an enhanced nutritional value, in the form of a better bioavailability and stability. It has a pleasant taste and colour. It can be used directly or concentrated or dried into powder for several applications into daily-consumed food products or other nutritional uses.
  • the described process has the major advantage of being natural and cost effective enabling improved delivery of multi- nutrients in the form of a combination of stabilized water- and fat-soluble compounds in their natural compositions, free of organic solvent residues.
  • this process increases miscibility and/or dispersibility in an aqueous system, stability, and bioavailability of bioactive compounds of wolfberry material, in particular, by using milk or milk proteins, soy milk or milk-like proteins from plants for extracting and delivering the multi-nutrients of functional ingredients of wolfberries.
  • a primary composition as described above can be used for delivering the multi-nutrients of functional ingredients of wolfberries with improved bioavailability, miscibility and stability .
  • bioactive compound is to be understood to mean molecules or components showing a biological activity or a health impact when orally or topically applied.
  • the primary composition comprises at least a part of the essential lipophilic and/or hydrophilic bioactive components of wolfberries .
  • the essential lipophilic and/or hydrophilic bioactive components are preferably selected from the group consisting of lipids, alkaloids, proteins, carbohydrates, glycosides, glycoproteins, carotenoids, polyphenolic compounds such as flavonoids, vitamins, minerals, or mixtures thereof.
  • the carotenoids may be selected from the group consisting of carotenes and xanthophylls such as lycopene, carotene, phytofluene, phytoene, canthaxanthin, beta-cryptoxanthin, capsanthin, lutein, zeaxanthin, or those in the form of fatty acid esters, or mixtures thereof.
  • glycoproteins are preferably selected from the group consisting of arabinogalactan proteins, in particular Lycium barbarum polysaccharide and macromolecules that can be detected by the beta-glucosyl Yariv reagent.
  • the flavonoids are preferably selected from the group consisting of flavones such as apigenin, luteolin or diosmetin, flavonols such as quercetin, myricetin, kaempferol, flavanones, anthocyanidins such as pelargonidin, malvidin, or isoflavones such as genistein, daidzein, or mixtures thereof.
  • flavones such as apigenin, luteolin or diosmetin
  • flavonols such as quercetin, myricetin, kaempferol, flavanones
  • anthocyanidins such as pelargonidin, malvidin
  • isoflavones such as genistein, daidzein, or mixtures thereof.
  • the primary composition of the present invention may contain at least the essential bioactive components of wolfberries or a part thereof, excluding insoluble fibers, in a milk or milk protein-containing carrier.
  • the milk carrier may be in the form of skimmed milk or whole milk from animal or plant origin (e. g. soy milk, juice or coconut milk, etc.) .
  • cow's milk or soy milk are used, depending on the primary composition which is desired.
  • the milk-containing carrier may be any edible liquid containing milk proteins such as caseins or whey proteins, for example.
  • Vegetable oils may optionally be added to the liquid medium.
  • the wolfberry material may be mixed and/or milled in said milk or milk protein-containing liquid medium in a respective ratio of about 1:1 to 1:1000, preferably from 1:5 to 1:50.
  • the mixing and/or milling step may be carried out at a temperature of from 1 to 95°C, preferably from about 20 to 80°C and more preferably from 40 to 80°C.
  • insoluble fibres may be at least partially removed to obtain an aqueous suspension.
  • the resulting primary composition may be further pasteurized and/or dried into a powder by techniques known in the art.
  • the primary composition obtained may also be in liquid or gel form.
  • the present invention thus provides a primary composition having a similar profile of the important nutrients as the whole fruit, it has a good stability, miscibility and bioavailability.
  • These compositions may be highly dispersible in an aqueous system, if the powder form is chosen. In this case, the powder is dispersible in cold or hot water, for example. It can equally well be added in milk.
  • Wolfberry can be administered to the subject in any suitable form using any suitable administration route.
  • composition of the present invention may be to be administered orally, enterally and/or parenterally.
  • composition of the present invention may be selected from the group consisting of a food product, a drink, a food additive, a dietary supplement, a nutraceutical , a nutritional formula, a formula for clinical nutrition or a pet food product .
  • a nutritional formula, a formula for clinical nutrition or a pet food product wolfberry may comprise from about 0.1 to about 40 weight-% of the food composition, preferably from about 3 to about 30 weight-%, more preferably from about 5 to about 20 weight-% In various embodiments, such compositions may comprise about 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, or 40 weight-% wolfberry.
  • a dietary supplement, or a nutraceutical, wolfberry When administered in a food additive, a dietary supplement, or a nutraceutical, wolfberry may comprise from about 0.1 to about 90 weight-% of the supplement, preferably from about 3 to about 70 weight-%, more preferably from about 5 to about 60 weight-%.
  • such compositions may comprise about 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 45, 50, 55, 60, 70, or about 80 weight-% wolfberry.
  • Those skilled in the art will understand that they can freely combine all features of the present invention described herein, without departing from the scope of the invention as disclosed. In particular, features described for the uses of the present invention may be applied to the composition of the present invention and vice versa.
  • Figures 1A and IB show Kaplan-Meier survival curves. Animals were culled after the first stroke incident had been identified .
  • Figure 2 shows the result of a typical hemorrhage stroke in the SHRsp rat brain.
  • Figure 3 shows inflammatory and antioxidant factor expression in brain tissue.
  • Figure 4 shows the effect of lacto-Wolfberry on blood pressure.
  • Spontaneously hypertensive rats of the stroke prone substrain have been shown to be susceptible to the early development of cerebral vascular lesions (Okamoto et al . , Circ Res 1974; 34-35 (suppl 1):143-153) and are largely considered as a good model for stroke in humans (Yamori et al . , Stroke. 1976 Jan-Feb; 7(1) :46-53) . Under hemodynamic stress, the thinning and fragmentation of internal elastic lamina are considered to result in aneurysmal development.
  • the animals were considered to have developed stroke when abnormal behavior, such as hemiparesis, was observed.
  • Kaplan- Meier survival curves revealed that SHRsp had a significantly higher stroke rate compared with control animals (WKY) .
  • the SHRsp-LW group was treated with a lacto wolfberry preparation which was prepared as described in WO2005/092121 : 53% wolfberry ; 29% skimmed milk powder and 18% maltodextrin . Lacto-wolfberry treatment successfully delayed the onset of the stroke incidence in SHRsp animals. 50% of animals developed stroke in the SHRsp group at day 90 whereas in the SHRsp-LW group at day 104 ( Figure 1A) .
  • Lacto-wolfberry successfully delayed the onset of hemorrhagic brain damage in SHRsp animals.
  • the beneficial effect of Lacto- wolfberry might be due to the reduction of TNF- expression, thereby preventing, reducing or treating the cerebral aneurysms development and rupture.
  • treatment of the Lacto-wolfberry had no effect on blood pressure in SHRsp, which implies that it can be applied in people with normal blood pressure who also need to prevent stroke but do not need to lower their blood pressure.
  • the study shows that wolfberry have a direct effect on preventing, reducing or treating the cerebral aneurysms process and its rupture, and the damage caused by cerebral aneurysms process and rupture .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition destinée au traitement, à l'amélioration ou à la prévention de troubles liés à une élasticité altérée des vaisseaux sanguins comprenant des baies de lyciet ou un extrait de celles-ci. Les baies de lyciet peuvent également être utilisées comme composant principal d'une composition, comprenant des baies de lyciet ou une partie de celles-ci et du lait ou un support contenant une protéine lactique dans la composition.
PCT/CN2011/083302 2011-12-01 2011-12-01 Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins WO2013078659A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201180075659.8A CN104010649A (zh) 2011-12-01 2011-12-01 改善血管弹性的天然成分
PCT/CN2011/083302 WO2013078659A1 (fr) 2011-12-01 2011-12-01 Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/083302 WO2013078659A1 (fr) 2011-12-01 2011-12-01 Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins

Publications (1)

Publication Number Publication Date
WO2013078659A1 true WO2013078659A1 (fr) 2013-06-06

Family

ID=48534637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/083302 WO2013078659A1 (fr) 2011-12-01 2011-12-01 Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins

Country Status (2)

Country Link
CN (1) CN104010649A (fr)
WO (1) WO2013078659A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727434B2 (fr) † 2004-03-19 2016-08-31 Nestec S.A. Administration des ingrédients fonctionnels
WO2023116621A1 (fr) * 2021-12-20 2023-06-29 Societe Des Produits Nestle S.A. Processus de préparation d'une composition de baies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101185463A (zh) * 2006-11-16 2008-05-28 马学亮 减肥保健早餐奶

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1927008A (zh) * 2006-10-17 2007-03-14 赵庆国 牛奶枸杞粉及其生产方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101185463A (zh) * 2006-11-16 2008-05-28 马学亮 减肥保健早餐奶

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAN XULIN ET AL.: "Development of Fructus Lycii Health Yoghurt", THE BEVERAGE INDUSTRY, vol. 10, no. 12, 31 December 2007 (2007-12-31), pages 14 - 16 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1727434B2 (fr) † 2004-03-19 2016-08-31 Nestec S.A. Administration des ingrédients fonctionnels
WO2023116621A1 (fr) * 2021-12-20 2023-06-29 Societe Des Produits Nestle S.A. Processus de préparation d'une composition de baies

Also Published As

Publication number Publication date
CN104010649A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
CA2699233C (fr) Symphorines occidentales et inflammation cutanee
JP5086801B2 (ja) 機能性成分の送達
JP5559453B2 (ja) カロテノイド化合物のシス異性体を含む組成物及び方法
JP2009508508A (ja) 水分散性組成物及びその調製方法
RU2004131193A (ru) Лечение заболеваний, связанных с дефектной коммуникацией посредством щелевых контактов
EP2464248A2 (fr) Composition comprenant une fraction d'insaponifiable
US20100190867A1 (en) Stable and bioavailable compositions of isomers of lycopene for skin and hair
US20150258038A1 (en) Stable and bioavailable compositions of isomers of carotenoids for skin and hair
WO2013078659A1 (fr) Ingrédients naturels améliorant l'élasticité des vaisseaux sanguins
EP2241198A1 (fr) Supplément de prévention de la mucosite et traitement
JP2005060338A (ja) プロアントシアニジン含有組成物
Baranwal et al. Utilization of Phytochemicals as Nutraceutical in the Prophylaxis of Dengue
JP2001145471A (ja) ムラサキサツマイモ由来の血液循環改善作用を有する食品素材
Bhatt et al. EVALUATION OF ACTUAL ANTIOXIDANT CAPACITY OF “JAMUN”(SYZYGIUM CUMINI) USING THE IN VITRO GASTROINTESTINAL MODEL
WO2006067864A1 (fr) Composition contenant de la proanthocyanidine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11876601

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11876601

Country of ref document: EP

Kind code of ref document: A1